Essilor Instruments has announced the addition of eye-light® by Espansione Group into its product offering. The device "combines Optimal Power Energy™ Intense Pulsed Light (OPE™ IPL) with Light Modulation™ Low-level Light Therapy (LM™ LLLT), to deliver targeted, condition-specific management for ocular surface diseases (OSD)."

OPE™ IPL and LM™ LLLT jointly leveraged on eye-light® have been shown to deliver greater improvements in tear film quality and patient symptoms (1) than competing IPL-only solutions, the company reports.

Paul Cumber, instruments director at EssilorLuxottica, commented: “This all-in-one approach to light therapy enables eye care practitioners to target the root cause of many ocular surface diseases, including dry eye. Offering this management pathway for dry eye and OSD helps expand the scope of the practice and will lead to meaningful improvements in the quality of life for patients with dry eye disease. It also helps strengthen patient trust and loyalty throughout their dry eye management journey, while elevating and differentiating the in-practice experience.”

Treatment is delivered through a course of up to four sessions, each lasting approximately 15 minutes on average. 

Combining these light therapies has been recognized in the TFOS DEWS III Management & Therapy Report (2) as a solution to manage OSD. Beyond symptom relief, clinical studies have demonstrated superior efficacy versus long-term eye-drop therapy, improving tear stability and clinical outcomes (3). In addition, research into the light therapies have shown long-lasting results maintained for up to 18 months (4).

For more information, please contact the Essilor Instruments team at gbinstruments@essilor.co.uk and visit ecp.essilor-pro.com/gb.